AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune (NASDAQ: ACIU) has announced a strategic restructuring to optimize its pipeline focus and extend its cash runway. The company will implement a 30% workforce reduction while concentrating on its three clinical-stage active immunotherapy programs and key small molecule programs targeting NLRP3 and Tau.
The restructuring will extend the company's cash runway through Q3 2027, supported by current cash resources of CHF 127.1 million as of June 30, 2025. The company maintains its clinical timeline guidance, with interim data expected from ACI-7104.056 in H2 2025 and ACI-24.060 in H1 2026.
The implementation will be completed by the end of 2025, with cost reductions becoming fully effective in early 2026. Affected employees will receive severance packages and support for new employment opportunities.
AC Immune (NASDAQ: ACIU) ha annunciato una ristrutturazione strategica volta a ottimizzare il proprio portafoglio e prolungare la disponibilit脿 di cassa. L'azienda proceder脿 con una riduzione del personale del 30%, concentrandosi sui tre programmi di immunoterapia attiva in fase clinica e sui principali programmi di piccole molecole mirati a NLRP3 e Tau.
La ristrutturazione estender脿 la liquidit脿 aziendale fino al terzo trimestre 2027 (Q3 2027), supportata da risorse liquide pari a CHF 127,1 milioni al 30 giugno 2025. L'azienda conferma la sua timeline clinica, con dati interim attesi per ACI-7104.056 nella seconda met脿 del 2025 e per ACI-24.060 nella prima met脿 del 2026.
L'attuazione sar脿 completata entro la fine del 2025 e le riduzioni di costo saranno pienamente efficaci all'inizio del 2026. I dipendenti interessati riceveranno pacchetti di buonuscita e supporto per la ricerca di nuove opportunit脿 di lavoro.
AC Immune (NASDAQ: ACIU) ha anunciado una reestructuraci贸n estrat茅gica para optimizar su cartera y ampliar su runway de efectivo. La compa帽铆a llevar谩 a cabo una reducci贸n del 30% de la plantilla, centrando sus esfuerzos en sus tres programas de inmunoterapia activa en fase cl铆nica y en sus programas clave de peque帽as mol茅culas dirigidos a NLRP3 y Tau.
La reestructuraci贸n prolongar谩 la disponibilidad de efectivo hasta el 3T de 2027 (Q3 2027), respaldada por recursos en efectivo por CHF 127,1 millones a fecha del 30 de junio de 2025. La compa帽铆a mantiene su calendario cl铆nico, con datos interinos esperados de ACI-7104.056 en la segunda mitad de 2025 y de ACI-24.060 en la primera mitad de 2026.
La implementaci贸n se completar谩 a fines de 2025 y las reducciones de costes estar谩n plenamente vigentes a principios de 2026. Los empleados afectados recibir谩n paquetes de indemnizaci贸n y apoyo para encontrar nuevas oportunidades laborales.
AC Immune (NASDAQ: ACIU)電� 韺岇澊頂勲澕鞚胳潉 斓滌爜頇旐晿瓿� 順勱笀 靻岇 旮瓣皠鞚� 鞐办灔頃橁赴 鞙勴暅 鞝勲灥鞝� 甑“臁办爼鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚鸽牓鞚� 30% 臧愳稌鞚� 鞁滍枆頃橁碃, 鞛勳儊 雼硠鞐� 鞛堧姅 靹� 臧�歆� 頇滌劚 氅挫棴鞖旊矔 頂勲攴鸽灗瓿� NLRP3 氚� Tau毳� 響滌爜頃橂姅 欤检殧 鞝�攵勳瀽 頂勲攴鸽灗鞐� 歆戩頃� 鞓堨爼鞛呺媹雼�.
鞚措矆 甑“臁办爼鞙茧 須岇偓鞚� 順勱笀 靻岇 鞁滌爯鞚� 2027雲� 3攵勱赴(Q3 2027)旯岇 鞐办灔霅橂┌, 2025雲� 6鞗� 30鞚� 旮办 CHF 1鞏�2710毵�鞚� 順勱笀 鞛愳洂鞚� 氚旐儠鞙茧 頃╇媹雼�. 須岇偓電� 鞛勳儊 鞚检爼 臧�鞚措崢鞀るゼ 鞙犾頃橂┌, ACI-7104.056鞚� 欷戧皠 瓴瓣臣電� 2025雲� 頃橂皹旮�, ACI-24.060鞚� 欷戧皠 瓴瓣臣電� 2026雲� 靸侂皹旮办棎 鞓堨儊霅╇媹雼�.
甑“臁办箻電� 2025雲� 毵愱箤歆� 鞕勲霅橂┌ 牍勳毄 鞝堦皭 須臣電� 2026雲� 齑堨棎 鞕勳爠頌� 氚滍湗霅� 鞓堨爼鞛呺媹雼�. 鞓來枼氚涬姅 歆侅洂霌れ棎瓴岆姅 韲挫 鞙勲旮堦臣 靸堧鞖� 鞚检瀽毽� 歆�鞗愳澊 鞝滉车霅╇媹雼�.
AC Immune (NASDAQ: ACIU) a annonc茅 une restructuration strat茅gique visant 脿 optimiser son pipeline et 脿 prolonger sa tr茅sorerie. La soci茅t茅 proc茅dera 脿 une r茅duction de 30 % des effectifs, en se concentrant sur ses trois programmes d'immunoth茅rapie active en phase clinique et sur ses programmes cl茅s de petites mol茅cules ciblant NLRP3 et Tau.
La restructuration permettra d'茅tendre la tr茅sorerie jusqu'au 3e trimestre 2027 (Q3 2027), soutenue par des liquidit茅s de 127,1 millions CHF au 30 juin 2025. La soci茅t茅 maintient ses pr茅visions cliniques, avec des donn茅es interm茅diaires attendues pour ACI-7104.056 au second semestre 2025 et pour ACI-24.060 au premier semestre 2026.
La mise en 艙uvre sera achev茅e d'ici la fin 2025 et les r茅ductions de co没ts seront pleinement effectives d茅but 2026. Les employ茅s concern茅s recevront des indemnit茅s de d茅part et un accompagnement pour retrouver un emploi.
AC Immune (NASDAQ: ACIU) hat eine strategische Umstrukturierung angek眉ndigt, um den Fokus des Portfolios zu optimieren und die Cash-Runtime zu verl盲ngern. Das Unternehmen wird eine 30%ige Reduktion der Belegschaft vornehmen und sich auf seine drei klinischen aktiven Immuntherapieprogramme sowie auf zentrale Small-Molecule-Programme gegen NLRP3 und Tau konzentrieren.
Die Umstrukturierung wird die Liquidit盲tsreichweite des Unternehmens bis Q3 2027 ausdehnen, gest眉tzt durch vorhandene Barmittel in H枚he von CHF 127,1 Millionen zum 30. Juni 2025. Das Unternehmen best盲tigt seinen klinischen Zeitplan; Zwischenwerte werden f眉r ACI-7104.056 in der zweiten Jahresh盲lfte 2025 und f眉r ACI-24.060 in der ersten Jahresh盲lfte 2026 erwartet.
Die Umsetzung wird bis Ende 2025 abgeschlossen sein, die Kostensenkungen werden Anfang 2026 voll wirksam. Betroffene Mitarbeitende erhalten Abfindungspakete und Unterst眉tzung bei der Stellensuche.
- Cash runway extended to Q3 2027, providing significant operational flexibility
- Maintained partnerships with major pharma companies (Janssen, Takeda, Lilly)
- Clinical timelines remain unchanged for key programs
- Strategic focus on late-stage clinical development and high-value candidates
- 30% workforce reduction impacting operational capacity
- Narrowing of pipeline focus may limit potential opportunities
- Restructuring costs and severance packages will impact short-term finances
Insights
AC Immune's 30% workforce reduction extends cash runway to Q3 2027 while focusing on late-stage immunotherapies and high-value candidates.
AC Immune's restructuring announcement represents a significant strategic shift to prioritize its most advanced assets. The 30% workforce reduction, while substantial, is designed to extend the company's
The pipeline prioritization is strategically sound, focusing on three key areas: (1) clinical-stage active immunotherapy programs with existing pharma partnerships (Janssen, Takeda, Lilly), (2) the NLRP3 inhibitor program targeting neuroinflammation, and (3) their Tau-targeting assets. This represents a pragmatic concentration on programs with both clinical advancement and partnership potential.
Most importantly, the company maintains its timeline guidance for key data readouts, including interim results from ACI-7104.056 (H2 2025) and ACI-24.060 (H1 2026). These milestones could serve as potential value inflection points and partnership triggers. The preservation of these timelines despite the restructuring suggests the workforce reduction is primarily affecting earlier-stage research programs rather than later-stage clinical operations.
While restructuring always carries execution risks, this appears to be a proactive measure to extend runway and strengthen the company's position for potential future partnering discussions rather than a desperate cost-cutting measure. The retention of key clinical timelines while extending cash runway by 6-9 months represents a balanced approach to the challenging environment for neurodegenerative disease drug development.
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
- Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around
30% - Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer鈥檚 and Parkinson鈥檚 diseases and progressing high value candidates enabling intracellular targeting
- Near term clinical milestones remain unchanged
- Cash resources of CHF 127.1 million as of June 30, 2025, now provides cash for operations to the end of Q3 2027 not including potential payments from partnering
Lausanne, Switzerland, September 4th, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that following a strategic review by executive management, the Company is sharpening its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, the Company will reduce its workforce by around
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: 鈥淲e are making meaningful progress with our product candidates to treat and prevent neurodegenerative diseases and are eagerly approaching multiple potentially transformational milestones over the next two years. This is true both in our ongoing collaborations with Janssen, Takeda and Lilly, and in our wholly-owned programs where progress will further strengthen opportunities for more partnering.
The actions we are taking now extend our cash runway to the end of Q3 2027, excluding anticipated business development milestone payments from existing or potential new business deals. It has been a challenging and carefully considered decision and I want to recognize all our colleagues whose professionalism, expertise and passion have resulted in many invaluable contributions to our mission over the years.
Going forward, we will focus our resources on our Phase 2 active immunotherapies and the development of our most exciting novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases, including NLRP3 and Tau.鈥�
AC Immune maintains its guidance on previously announced timelines with interim clinical data from both ACI-7104.056 and ACI-24.060 expected in H2 2025 and H1 2026, respectively.
In accordance with Swiss employment law a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. This will include, but will not be limited to, severance packages, and support in seeking new employment, coaching or training opportunities. AC Immune foresees the full implementation of these changes enacted by the end of 2025 and the reduction of costs to become fully effective early in 2026.
About听AC Immune SA听
AC Immune SA听is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer鈥檚 disease, Parkinson鈥檚 disease, and NeuroOrphan indications driven by misfolded proteins. The Company鈥檚 two clinically validated technology platforms, SupraAntigen庐 and Morphomer庐, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development.听AC Immune听has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >
SupraAntigen庐 is a registered trademark of听AC Immune SA听in the following territories: AU, EU, CH, GB, JP, RU, SG and听USA. Morphomer庐 is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP,听Investor Relations听& Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 贰尘补颈濒:听[email protected] | 听 |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 贰尘补颈濒:听[email protected] | 听 |
Forward looking statements
This press release contains statements that constitute 鈥渇orward-looking statements鈥� within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune鈥檚 strategies or expectations. In some cases, you can identify these statements by forward-looking words such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥渁nticipates,鈥� 鈥渂elieves,鈥� 鈥渆stimates,鈥� 鈥減redicts,鈥� 鈥減rojects,鈥� 鈥減otential,鈥� 鈥渙utlook鈥� or 鈥渃ontinue,鈥� and other comparable terminology. Forward-looking statements are based on management鈥檚 current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions 鈥淚tem 3. Key Information 鈥� Risk Factors鈥� and 鈥淚tem 5. Operating and Financial Review and Prospects鈥� in AC Immune鈥檚 Annual Report on Form 20-F and other filings with the听Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and听AC Immune听does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
FAQ
What is the extent of AC Immune's (ACIU) workforce reduction announced in September 2025?
How long will AC Immune's (ACIU) cash runway extend after the restructuring?
What are the key clinical programs AC Immune (ACIU) is focusing on after restructuring?
When will AC Immune (ACIU) report interim clinical data for its key programs?
What support will AC Immune (ACIU) provide to affected employees?
